Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Novartis Pharmaceuticals
Novartis Pharmaceuticals
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
53 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Novartis Investigative Site
CABA, Buenos Aires, Argentina
Recruiting - Novartis Investigative Site
Buenos Aires, Argentina
Recruiting
- Novartis Investigative Site
Belo Horizonte, Minas Gerais, Brazil
Recruiting - Novartis Investigative Site
Recife, Pernambuco, Brazil
Recruiting - Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Recruiting - Novartis Investigative Site
Botucatu, São Paulo, Brazil
Recruiting - Novartis Investigative Site
São Paulo, São Paulo, Brazil
Recruiting - Novartis Investigative Site
Salvador, Brazil
Recruiting
- Novartis Investigative Site
Toronto, Ontario, Canada
Active, not recruiting
- Novartis Investigative Site
Beijing, China
Recruiting - Novartis Investigative Site
Shanghai, China
Recruiting
- Novartis Investigative Site
Prague, Czechia
Active, not recruiting
- Novartis Investigative Site
Montpellier, France
Recruiting - Novartis Investigative Site
Paris, France
Recruiting - Novartis Investigative Site
Paris, France
Active, not recruiting - Novartis Investigative Site
Toulouse, France
Recruiting
- Novartis Investigative Site
Erlangen, Germany
Active, not recruiting - Novartis Investigative Site
Essen, Germany
Recruiting - Novartis Investigative Site
Hamburg, Germany
Active, not recruiting - Novartis Investigative Site
Heidelberg, Germany
Recruiting - Novartis Investigative Site
Mainz, Germany
Recruiting
- Novartis Investigative Site
Heraklion Crete., Greece
Active, not recruiting - Novartis Investigative Site
Thessaloniki, Greece
Active, not recruiting
- Novartis Investigative Site
Petah Tikva, Israel
Active, not recruiting - Novartis Investigative Site
Petah Tikva, Israel
Recruiting
- Novartis Investigative Site
Bari, BA, Italy
Recruiting - Novartis Investigative Site
Ranica, BG, Italy
Recruiting - Novartis Investigative Site
Roma, RM, Italy
Recruiting
- Novartis Investigative Site
Nagoya, Aichi-ken, Japan
Active, not recruiting - Novartis Investigative Site
Asahikawa, Hokkaido, Japan
Active, not recruiting - Novartis Investigative Site
Sapporo, Hokkaido, Japan
Completed - Novartis Investigative Site
Takatsuki, Osaka, Japan
Active, not recruiting - Novartis Investigative Site
Ohtsu, Shiga, Japan
Recruiting - Novartis Investigative Site
Hachiōji, Tokyo, Japan
Recruiting - Novartis Investigative Site
Niigata, Japan
Active, not recruiting
- Novartis Investigative Site
Leiden, South Holland, Netherlands
Active, not recruiting
- Novartis Investigative Site
Pamplona, Navarre, Spain
Recruiting - Novartis Investigative Site
Barcelona, Spain
Completed - Novartis Investigative Site
Madrid, Spain
Recruiting - Novartis Investigative Site
Madrid, Spain
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 3 Oct 2019
- Primary completion
- 30 May 2036
- Completion
- 30 May 2036
- Last update posted
- 7 Aug 2026
- Registered enrollment
- 225
- Registry id
- NCT03955445
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.